To summarize the role of prostate MRI in the assessment and treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS).
BPH/LUTS is a very common source of morbidity in aging men. mpMRI has become an increasingly popular modality for prostate imaging due to its ability to provide exceptional anatomic detail. This has allowed for MRI classification of BPH and detailed assessment of response to various BPH treatment modalities, including simple prostatectomy and transurethral resection of the prostate as well as newer methods like UroLift and prostatic artery embolization. MRI will continue to be a useful tool in the diagnosis and management of BPH/LUTS and provides useful information about the efficacy of a variety of available treatment options. Further studies are needed to fully characterize the effects of newer BPH interventions on mpMRI.
Current urology reports. 2020 Oct 26*** epublish ***
Stephanie M Walker, Baris Turkbey
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room B3B85, MD, 20892, Bethesda, USA., Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room B3B85, MD, 20892, Bethesda, USA. .